{"id":62138,"date":"2026-04-01T23:44:14","date_gmt":"2026-04-01T15:44:14","guid":{"rendered":"https:\/\/flcube.com\/?p=62138"},"modified":"2026-04-01T23:44:16","modified_gmt":"2026-04-01T15:44:16","slug":"rui-therapeutics-secures-nmpa-approval-for-kn5501-car-nk-therapy-in-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62138","title":{"rendered":"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Rui Therapeutics<\/strong>, a China-based cell therapy developer, announced it has received approval from the <strong>National Medical Products Administration (NMPA)<\/strong> to initiate clinical studies for <strong>KN5501<\/strong>, a <strong>CD19-targeted CAR-NK therapy<\/strong>, in three severe autoimmune conditions: <strong>primary Sj\u00f6gren&#8217;s syndrome<\/strong>, <strong>systemic sclerosis<\/strong>, and <strong>refractory lupus nephritis<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-plan\">Clinical Development Plan<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Patient Population<\/th><th>Current Treatment Gap<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Sj\u00f6gren&#8217;s Syndrome<\/strong><\/td><td>Inadequate response to prior standard therapy<\/td><td>Limited effective options for refractory cases<\/td><\/tr><tr><td><strong>Systemic Sclerosis<\/strong><\/td><td>No remission or rapid progression after adequate treatment<\/td><td>High unmet need in progressive disease<\/td><\/tr><tr><td><strong>Refractory Lupus Nephritis<\/strong><\/td><td>Treatment-resistant kidney involvement in SLE<\/td><td>Significant morbidity despite current therapies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-kn5501-characteristics\">KN5501 Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform<\/strong>: CD19-targeted CAR-NK (Chimeric Antigen Receptor Natural Killer) cell therapy<\/li>\n\n\n\n<li><strong>Target<\/strong>: CD19-positive B cells<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Precise recognition and deep elimination of pathogenic B cells<\/li>\n\n\n\n<li><strong>Immunological Effect<\/strong>: Blocks aberrant immune responses while inducing immune system reconstitution<\/li>\n\n\n\n<li><strong>Therapeutic Goal<\/strong>: Deep or complete remission at root cause level<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-differentiated-approach\">Differentiated Approach<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>B Cell Depletion<\/strong>: Comprehensive elimination of CD19+ B cells including plasma cell precursors<\/li>\n\n\n\n<li><strong>Immune Reset<\/strong>: Promotes reconstitution of healthy immune system<\/li>\n\n\n\n<li><strong>Treatment Freedom<\/strong>: Aims to eliminate long-term dependence on corticosteroids and immunosuppressants<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong>: NK cell platform potentially offers improved safety versus CAR-T approaches<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-novel-application-of-cell-therapy\">Novel Application of Cell Therapy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Paradigm Shift<\/strong>: First application of CAR-NK technology in autoimmune diseases<\/li>\n\n\n\n<li><strong>Curative Potential<\/strong>: Moves beyond symptom management toward disease modification<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Demonstrates versatility of CAR-NK platform beyond oncology<\/li>\n\n\n\n<li><strong>Chinese Innovation<\/strong>: Represents cutting-edge cell therapy development in China<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-patient-impact\">Patient Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Quality of Life<\/strong>: Substantial improvement through elimination of chronic immunosuppression<\/li>\n\n\n\n<li><strong>Side Effect Reduction<\/strong>: Minimizes long-term complications from corticosteroids and immunosuppressants<\/li>\n\n\n\n<li><strong>Disease Control<\/strong>: Potential for sustained remission without continuous medication<\/li>\n\n\n\n<li><strong>Economic Benefit<\/strong>: Reduces lifetime healthcare costs associated with chronic autoimmune management<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-analysis\">Market Opportunity Analysis<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-target-disease-populations\">Target Disease Populations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sj\u00f6gren&#8217;s Syndrome<\/strong>: Affects 0.5-1% of general population, with significant refractory subset<\/li>\n\n\n\n<li><strong>Systemic Sclerosis<\/strong>: Rare but severe connective tissue disease with high mortality<\/li>\n\n\n\n<li><strong>Lupus Nephritis<\/strong>: Occurs in 40-60% of SLE patients, leading cause of morbidity\/mortality<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-potential\">Commercial Potential<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Premium Pricing<\/strong>: Cell therapy pricing model supports high-value proposition<\/li>\n\n\n\n<li><strong>Orphan Indications<\/strong>: Several target populations qualify for orphan drug incentives<\/li>\n\n\n\n<li><strong>Global Applicability<\/strong>: Successful development supports international regulatory submissions<\/li>\n\n\n\n<li><strong>Platform Expansion<\/strong>: Success enables expansion to additional autoimmune indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Standard<\/strong>: Chronic immunosuppression with corticosteroids, biologics, and cytotoxic agents<\/li>\n\n\n\n<li><strong>Emerging Alternatives<\/strong>: B cell depletion with anti-CD20 antibodies (rituximab, ocrelizumab)<\/li>\n\n\n\n<li><strong>Cell Therapy Innovation<\/strong>: First-in-class CAR-NK approach offers potential advantages over antibody-mediated depletion<\/li>\n\n\n\n<li><strong>Durability Advantage<\/strong>: Single or limited-dose cell therapy versus chronic biologic administration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-next-steps\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Stage<\/strong>: First-in-human studies expected to initiate in 2026<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: NMPA approval enables comprehensive clinical development in China<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: Scalable CAR-NK production platform critical for commercial viability<\/li>\n\n\n\n<li><strong>Global Strategy<\/strong>: Potential for international partnerships following Chinese clinical validation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial potential for KN5501. Actual results may differ due to risks including clinical trial outcomes, manufacturing challenges, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62139,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[65,77,62,24,4671],"class_list":["post-62138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-rare-orphan-disease-drugs","tag-rui-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National Medical Products Administration (NMPA) to initiate clinical studies for KN5501, a CD19-targeted CAR-NK therapy, in three severe autoimmune conditions: primary Sj\u00f6gren&#039;s syndrome, systemic sclerosis, and refractory lupus nephritis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62138\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National Medical Products Administration (NMPA) to initiate clinical studies for KN5501, a CD19-targeted CAR-NK therapy, in three severe autoimmune conditions: primary Sj\u00f6gren&#039;s syndrome, systemic sclerosis, and refractory lupus nephritis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62138\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T15:44:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T15:44:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0106.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62138#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62138\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases\",\"datePublished\":\"2026-04-01T15:44:14+00:00\",\"dateModified\":\"2026-04-01T15:44:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62138\"},\"wordCount\":506,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62138#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0106.webp\",\"keywords\":[\"Auto-immune\",\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"Rare \\\/ orphan disease drugs\",\"Rui Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62138#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62138\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62138\",\"name\":\"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62138#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62138#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0106.webp\",\"datePublished\":\"2026-04-01T15:44:14+00:00\",\"dateModified\":\"2026-04-01T15:44:16+00:00\",\"description\":\"Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National Medical Products Administration (NMPA) to initiate clinical studies for KN5501, a CD19-targeted CAR-NK therapy, in three severe autoimmune conditions: primary Sj\u00f6gren's syndrome, systemic sclerosis, and refractory lupus nephritis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62138#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62138\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62138#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0106.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0106.webp\",\"width\":1080,\"height\":608,\"caption\":\"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62138#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National Medical Products Administration (NMPA) to initiate clinical studies for KN5501, a CD19-targeted CAR-NK therapy, in three severe autoimmune conditions: primary Sj\u00f6gren's syndrome, systemic sclerosis, and refractory lupus nephritis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62138","og_locale":"en_US","og_type":"article","og_title":"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases","og_description":"Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National Medical Products Administration (NMPA) to initiate clinical studies for KN5501, a CD19-targeted CAR-NK therapy, in three severe autoimmune conditions: primary Sj\u00f6gren's syndrome, systemic sclerosis, and refractory lupus nephritis.","og_url":"https:\/\/flcube.com\/?p=62138","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-01T15:44:14+00:00","article_modified_time":"2026-04-01T15:44:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0106.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62138#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62138"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases","datePublished":"2026-04-01T15:44:14+00:00","dateModified":"2026-04-01T15:44:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62138"},"wordCount":506,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62138#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0106.webp","keywords":["Auto-immune","Cell-therapy","Clinical trial approval \/ initiation","Rare \/ orphan disease drugs","Rui Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62138#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62138","url":"https:\/\/flcube.com\/?p=62138","name":"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62138#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62138#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0106.webp","datePublished":"2026-04-01T15:44:14+00:00","dateModified":"2026-04-01T15:44:16+00:00","description":"Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National Medical Products Administration (NMPA) to initiate clinical studies for KN5501, a CD19-targeted CAR-NK therapy, in three severe autoimmune conditions: primary Sj\u00f6gren's syndrome, systemic sclerosis, and refractory lupus nephritis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62138#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62138"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62138#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0106.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0106.webp","width":1080,"height":608,"caption":"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62138#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0106.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62138"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62138\/revisions"}],"predecessor-version":[{"id":62140,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62138\/revisions\/62140"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62139"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}